Skip to Main Content

Paper Details

Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.
Vaccine
3
2021
H7N9, HAI, MF59, MN, guttate psoriasis, human, influenza A (H7N9) infections, lichen planus
Author NameAffiliation
Mark J MulliganThe Hope Clinic of the Emory Vaccine Center, Emory University School of Medicine
Sharon E FreySaint Louis University School of Medicine
Kathryn M EdwardsVanderbilt University
  • 1 - 3

Datasets

Release 1.2